GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting

Rhea-AI Summary

GRAIL (Nasdaq: GRAL) reported full NHS-Galleri trial results at the 2026 ASCO Meeting. In 142,250 adults screened annually with the Galleri blood test plus standard screening versus standard screening alone, the primary endpoint—a reduction in combined Stage III/IV diagnoses in 12 cancers—was not met.

However, a pre-specified secondary endpoint showed Stage IV diagnoses for these cancers fell by 9%, 22% and 26% in the first, second and third rounds, for a 14% overall reduction. Stage I-II diagnoses rose 16%, screen-detected cancers increased four-fold, emergency-presenting cancers declined 25%, and no serious related adverse events were reported.

AI-generated analysis. Not financial advice.

Positive

• Stage IV diagnoses in 12 prespecified cancers fell 14% overall, up to 26% in round three
• Stage I-II cancer diagnoses for 12 prespecified cancers increased by 16% after three rounds
• Screen-detected cancers increased four-fold when Galleri was added to standard screening
• Cancers diagnosed after emergency presentation decreased by 25% with Galleri screening
• Galleri test specificity was 99.55%, with a low 0.45% false positive rate
• Positive predictive value reached 52.0% overall and 58.0% in the first round
• No serious related adverse events were reported over three screening rounds

Negative

• Primary endpoint of reducing combined Stage III/IV cancers was not met (IRR 1.03, p=0.6324)
• Combined Stage III/IV diagnoses increased 19% in the first prevalent screening round
• Episode sensitivity was 54.7% for 12 prespecified cancers and 30.7% across all cancers

Key Figures

Trial participants: 142,250 participants Stage IV reduction: 22% & 26% reductions Overall Stage IV change: 14% reduction +5 more

8 metrics

Trial participants 142,250 participants NHS-Galleri randomized trial population

Stage IV reduction 22% & 26% reductions Stage IV diagnoses in 2nd and 3rd screening rounds for 12 cancers

Overall Stage IV change 14% reduction Pre-specified secondary endpoint across 12 cancers

Early-stage increase 16% increase Stage I–II diagnoses after three screening rounds in 12 cancers

Cancer detection rate 0.48% 937 cancers among 1,801 positives over three rounds

Positive predictive value 52.0% overall; 58.0% first round Galleri test PPV in NHS-Galleri trial

Specificity 99.55% specificity; 0.45% false positive rate Galleri test performance over three rounds

CSO accuracy 92.5% Cancer Signal of Origin accuracy in trial

Market Reality Check

Price: $71.68 Vol: Volume 1,111,932 is 1.64x...

high vol

$71.68 Last Close

Volume Volume 1,111,932 is 1.64x the 20-day average of 676,137, indicating elevated pre-news activity. high

Technical Price 71.68 is trading above the 200-day MA at 69.49, despite a -3.03% daily move and sitting 39.68% below the 52-week high.

Peers on Argus

GRAL fell 3.03% with elevated volume, while close diagnostics peers showed mixed...

1 Up

GRAL fell 3.03% with elevated volume, while close diagnostics peers showed mixed action: NEOG (-3.76%), TWST (-3.21%) down, but OPK (+1.39%), NEO (+2.89%), CDNA (+0.71%) up. Momentum scanner only flagged MYGN (+5.79%) on the upside, reinforcing a stock-specific move rather than a broad sector rotation.

Historical Context

5 past events · Latest: May 27 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 27	Inducement RSU grants	Neutral	+3.5%	Announced RSU inducement grants to 56 new non-executive employees under incentive plan.
May 26	Conference participation	Neutral	+3.6%	Disclosure of upcoming presentation at Goldman Sachs Global Healthcare Conference with webcast access.
May 21	Conference participation	Neutral	-1.0%	Announcement of Jefferies Global Healthcare Conference appearance and webcast availability.
May 05	Earnings and pipeline	Positive	+15.3%	Reported Q1 2026 revenue growth, Galleri volume expansion, strong cash, and FDA PMA acceptance.
Apr 30	Conference participation	Neutral	-0.8%	Announced BofA Securities healthcare conference presentation with webcast access for investors.

Pattern Detected

Recent stock reactions have been positive to both earnings and routine corporate updates, with no recorded negative post-news moves in the last five events.

Recent Company History

Over the last months, GRAIL has focused investor attention on Galleri and large clinical programs. An 8-K on May 5, 2026 highlighted Q1 revenue of $40.8M, strong Galleri growth, and FDA PMA acceptance, which coincided with a +15.35% move. Conference presentations and an inducement grant release around late April–May generally saw modest positive or neutral reactions. Today’s NHS-Galleri readout fits the ongoing narrative of scaling Galleri with large real-world datasets.

Market Pulse Summary

This announcement details full NHS-Galleri trial results, highlighting a 14% reduction in Stage IV c...

Analysis

This announcement details full NHS-Galleri trial results, highlighting a 14% reduction in Stage IV cancers and a 16% increase in Stage I–II diagnoses over three screening rounds, despite the primary Stage III/IV endpoint not being met. The data build on earlier disclosures that large trials would read out at ASCO 2026. Investors may watch for peer-reviewed publication, regulatory interactions around Galleri, and how these outcomes influence future guideline or health-system adoption decisions.

Key Terms

multi-cancer early detection, positive predictive value, specificity, cancer signal of origin, +2 more

6 terms

multi-cancer early detection medical

"The NHS-Galleri trial is the first and only randomized, controlled trial of a multi-cancer early detection (MCED) test"

A multi-cancer early detection test is a medical screening tool—often a simple blood test—that looks for biological signals, such as abnormal DNA or protein patterns, that could indicate many different cancers before symptoms appear. For investors it matters because successful tests can reshape demand for diagnostics, influence healthcare spending and insurance coverage, and create new revenue streams or risks for companies across diagnostics, treatment and screening services; think of it as a smoke alarm that can warn of problems throughout an entire house rather than just one room.

positive predictive value medical

"The Galleri test's performance – positive predictive value (PPV), specificity and Cancer Signal of Origin (CSO) accuracy – was consistent"

Positive predictive value is a measure of how likely it is that a positive result actually indicates a true positive. For investors, it helps assess how reliable a signal or indicator is in predicting real opportunities or risks, similar to how knowing that a weather forecast predicts rain accurately helps you decide whether to carry an umbrella. A higher positive predictive value means greater confidence that a positive signal truly reflects a meaningful event.

specificity medical

"PPV was 52.0% overall and 58.0% in the first screening round. Specificity was 99.55%, resulting in a low false positive rate"

Specificity measures how well a diagnostic test or screening correctly identifies people who do not have a condition — the percentage of healthy cases the test labels as negative. Think of it as a smoke alarm that stays quiet when there’s no fire; high specificity means fewer false alarms. For investors, specificity affects regulatory approval, clinical adoption, follow-up costs, and the perceived reliability and market potential of medical products.

cancer signal of origin medical

"positive predictive value (PPV), specificity and Cancer Signal of Origin (CSO) accuracy – was consistent"

Cancer signal of origin is the determination of the tissue or organ where a detected cancer-related biological signal most likely began, for example pinpointing whether abnormal molecules in a blood test came from the lung, colon, or another site. Investors should care because knowing the origin improves diagnostic accuracy, guides treatment decisions, and affects a test or therapy’s market value and regulatory approval potential—similar to finding a building’s address after spotting smoke, which turns a vague warning into a clear action plan.

secondary endpoint medical

"Overall, in this pre-specified secondary endpoint, a 14% reduction in Stage IV cancers was observed."

A secondary endpoint is a predefined, additional measure used alongside the main goal of a clinical study to capture other important effects of a treatment, such as symptom improvement, quality of life, or biomarker changes. For investors, secondary endpoints matter because positive results can strengthen confidence in a drug’s overall benefit, influence regulatory decisions or labeling, and reduce risk if the primary goal is uncertain — think of them as supporting evidence or backup goals that make the overall story more persuasive.

randomized, controlled trial medical

"The NHS-Galleri trial is the first and only randomized, controlled trial of a multi-cancer early detection (MCED) test"

A randomized, controlled trial assigns participants by chance into two or more groups—one receiving the treatment being tested and the other receiving a standard treatment or placebo—so outcomes can be fairly compared. Think of it like flipping a coin to place people into different teams to avoid bias; investors use results from these trials as strong evidence about a drug or medical device’s real benefits and risks, which can materially affect regulatory approval, market potential, and company value.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

No Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round  

Annual Galleri^® Blood Test Reduced Stage IV Diagnoses of 12 Prespecified Cancers by 22% and 26% in the Second and Third Screening Rounds, Respectively

Galleri Increased Cancer Detection Rate by Four-Fold When Added to Standard of Care Screening and Reduced Cancer Diagnosis Through Emergency Presentation by 25%

Annual Testing With Galleri Increased Stage I-II Cancer Diagnoses by 16% When Added to Standard of Care

GRAIL to Host Analyst Call From 2026 ASCO Annual Meeting

MENLO PARK, Calif., May 30, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced detailed clinical utility, performance and safety results from its landmark NHS-Galleri trial in an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting¹.

The NHS-Galleri trial is the first and only randomized, controlled trial of a multi-cancer early detection (MCED) test and evaluated annual screening with the Galleri ^® test in England's National Health Service (NHS) over three years in 142,250 demographically representative participants aged 50 to 77 at enrollment. GRAIL collaborated with NHS England on the objectives of this study, based on NHS priorities to reduce Stage III and IV cancers.

"The goal of multi-cancer early detection is to find more cancers earlier, when they are more treatable and potentially curable, so that patients have the chance of living longer and more productive lives," said Josh Ofman, MD, MSHS, President and CEO-Elect at GRAIL. "The NHS-Galleri trial provides a wealth of data that support the use of the Galleri test to reduce the burden of metastatic Stage IV cancer and increase the number of cancers found earlier through screening at population scale. Importantly, Galleri found more Stage I and II cancers than all cancers found through NHS' existing single cancer screenings combined. By the third round of screening in this trial, Stage IV cancer diagnoses fell by more than a quarter, when treatment with curative intent may be possible."

Finding Cancers Earlier
The NHS-Galleri trial evaluated a combined primary endpoint of Stage III and IV diagnoses in a pre-specified group of 12 deadly cancers² when the Galleri test was added to standard of care screening in England (breast, bowel, cervical and high risk lung cancers) versus standard of care screening alone; however, there was no statistically significant difference within a 1-year follow up window after the last appointment. Follow-up will continue, with further results published as available.

Sir Harpal Kumar, Chief Scientific Officer and President, Global Clinical and Medical Affairs at GRAIL, explained the reasons behind the Stage III and IV result: "We saw a substantial decrease in Stage IV cancers, but this was outweighed by an overall increase in the number of Stage III cancers, particularly in the prevalent screening round. We believe the Stage III increase was driven in part by a number of Stage IV cancers being shifted to earlier stages, including at Stage III, and the fact that many more cancers overall were found earlier through screening in the intervention arm, while the equivalent cancers may not yet have been diagnosed in the control arm. We would expect to see more of these as yet undiagnosed late stage cancers being found in the control arm with longer follow up. In addition, the trial has revealed just how much undiagnosed and uninvestigated Stage III cancer is already prevalent in the population before any screening commences. Finding these cancers earlier means we can start treating those patients with the urgency needed and, in many cases, with the opportunity of curative intent."

One of the aims of screening is to reduce the incidence of metastatic late stage cancer. In the Galleri arm, Stage IV cancer diagnoses decreased with each year of sequential screening, with a 9% reduction in the first ("prevalent") screening round, a 22% reduction in the second round, and a 26% reduction in the third round in the pre-specified group of 12 cancers. The prevalent round detects undiagnosed cancers already present in the population at the time of initial screening, while subsequent "incident" rounds detect cancers that develop or progress between screening rounds and become detectable. Thus, the incident rounds most closely approximate the likely steady-state impact of an annual screening program. Overall, in this pre-specified secondary endpoint, a 14% reduction in Stage IV cancers was observed. These results were nominally statistically significant. Similar reductions of 20% or more were observed in the second and third screening rounds for all stageable cancers.

"As a lung cancer doctor, I see the clinical importance of diagnosing cancer at an earlier stage, when treatment is more likely to be curative," said Professor Charles Swanton, thoracic medical oncologist at University College London Hospital, and one of the NHS-Galleri trial's chief investigators. "The NHS-Galleri trial tested whether adding the Galleri blood test to NHS screening could reduce the combined number of cancers diagnosed at Stage III or IV over three years. The primary endpoint was not met. However, a pre-specified secondary endpoint did show a greater than 20% reduction in Stage IV cancers, with the effect strengthening by the third year of screening. The Stage IV reduction is clinically meaningful because for many cancers there is a real gulf in outlook between a Stage IV diagnosis and one caught earlier. The hope is that for more patients the conversation can be about treating cancer with curative intent rather than managing it palliatively."

Within the overall trend of Stage IV reduction, in an exploratory analysis, meaningful reductions in Stage IV diagnoses were observed in cancer types where 5-year survival is substantially higher when diagnosed at Stage III versus IV. For example, Stage IV diagnoses were reduced by 57.1% in esophageal cancer and 34.4% in colorectal cancer in the incident rounds. The five-year survival rates in England are significantly higher in Stage III than Stage IV for each of these cancers: 24.7% vs 6.2% for esophageal cancer, 64.2% vs 11.0% for colorectal cancer.

"For most cancer patients, there is a real difference between being diagnosed and being treated with a possibility of a cure versus being diagnosed at Stage IV and only being offered treatment that could manage symptoms and side effects or potentially prolong life for months or a few years. This is why it is critical to detect cancer at earlier stages, especially before distant metastases. Patients live longer when they are diagnosed before their cancer spreads to other parts of the body," said Sally Werner, RN, BSN, MSHA, Chief Executive Officer at Cancer Support Community, a global nonprofit advocacy organization. "The Galleri study results show promise and bring hope to people concerned about cancer that it might be detected earlier, improving patient outcomes and allowing more patients treatment options that offer potential cures. The fact that this screening is available with a simple blood test that could be done at any healthcare visit could make this a game changer in increased screening and earlier diagnosis, which could reduce a large portion of the persistent cancer disparities we see."

Relative Incidence Rate of Combined Stage III/IV Cancers Decreased After the First Round of Screening in the Pre-Specified Group of 12 Cancers; Relative Incidence Rate of Stage IV Cancers Decreased Each Screening Round.

	Stage III/IV Cancers Diagnosed		Stage IV Cancers Diagnosed
	Incidence Rate Ratio	Intervention vs Control (% Difference)	Incidence Rate Ratio	Intervention vs Control (% Difference)
After 3 Screening Rounds	1.03 (0.92, 1.14) p=0.6324	⬆3%	0.86 (0.744, 0.998)	⬇14%
First Screening Round (Prevalent)	1.19 (0.98, 1.43)	⬆19%	0.91 (0.71, 1.18)	⬇9%
Second Screening Round (Incident)	0.95 (0.77, 1.17)	⬇5%	0.78 (0.57, 1.06)	⬇22%
Third Screening Round (Incident)	0.88 (0.73, 1.07)	⬇12%	0.74 (0.57, 0.95)	⬇26%

Along with the decrease in Stage IV cancer incidence, Stage I and II cancers diagnosed increased by 16% for the 12 prespecified cancer types after three rounds of screening, including large increases in many types typically diagnosed late, such as ovarian, esophageal, pancreatic and liver cancers. 

Nigel, 70, from the North East of England, took part in the NHS-Galleri trial and was diagnosed with Stage I head and neck cancer after receiving a cancer signal detected Galleri test result. "The fact that the cancer was Stage I meant it had likely been caught much earlier than would have otherwise been the case," Nigel said. "The surgery was less invasive, so that aided my recovery. And the horror stories I was presented with about the number of days in hospital and having to learn to drink and eat again - luckily none of that happened in my case."

Finding More Cancers With Robust Performance and Favorable Safety
The addition of the Galleri test to standard-of-care cancer screenings led to a four-fold increase in screen-detected cancers and a 21% decrease in the number of clinically detected cancers after symptomatic presentation. Further, the addition of MCED screening was associated with cancers diagnosed after emergency presentation decreasing by 25%.

Eric Sue, M.D., a primary care physician of internal medicine at the Sue Medical Group in Los Angeles, noted: "There is a distinct difference between the objectives of a therapeutic drug trial and those of a cancer screening trial, where the totality of the data must be carefully considered. In the NHS-Galleri trial, the observed greater than 20% reduction in stage IV cancer diagnoses and the four-fold increase in cancer detection compared with standard screening alone are both highly compelling findings. Shifting cancers away from metastatic presentation toward earlier-stage detection—while identifying substantially more cancers overall—creates more opportunities to intervene when curative treatment may still be possible and, most importantly, where the opportunity to reduce cancer mortality may be greatest."

The Galleri test's performance – positive predictive value (PPV), specificity and Cancer Signal of Origin (CSO) accuracy – was consistent with the range previously reported from GRAIL's North American studies. Over three screening rounds, 1,801 participants (0.91%) had a positive MCED test result and 937 were diagnosed with cancer, for a cancer detection rate of 0.48%. PPV was 52.0% overall and 58.0% in the first screening round. Specificity was 99.55%, resulting in a low false positive rate of 0.45%. CSO accuracy was 92.5%. Episode sensitivity – the ability to detect cancers that were diagnosed within 12 months after each Galleri screening blood draw - was 54.7% for the 12 prespecified cancer types and 30.7% across all cancer types.

"Our current recommended screening tests only find around 14% of newly diagnosed cancers each year in the US and around 6% in England. In finding four times as many cancers compared to the standard screening programs combined, we are identifying many more asymptomatic patients with undiagnosed disease months or even years earlier than currently possible," said Kumar. "Galleri represents a potential transformational shift in cancer detection, moving us to a more comprehensive proactive approach. As treatment options continue to advance, screening frameworks must evolve in parallel. Multi-cancer early detection provides an opportunity to reshape screening around an evolving goal: detecting more cancers when there is an opportunity for cure."

There were no serious related adverse events reported in the trial, reaffirming the safety profile of the test.

The results of the NHS-Galleri trial will be submitted for publication in a peer-reviewed medical journal.

"We are deeply grateful to the more than 142,000 participants who took part in this study, as well as to the NHS, The Cancer Prevention Trials Unit at Queen Mary University of London, Cancer Alliances, investigators, and clinical teams whose dedication made this landmark trial possible," said Professor Richard Neal, Professor of Primary Care at University of Exeter, General Practitioner, St. Leonard's Practice, and one of the NHS-Galleri trial's chief investigators.

GRAIL to Host Analyst Call From 2026 ASCO Annual Meeting 
GRAIL will host an analyst call to discuss clinical study results presented at ASCO tomorrow, Sunday, May 31, 2026, beginning at 4 p.m. PT/6 p.m. CT.

A link to the live webcast and recorded replay will be available at the investor relations section of GRAIL's website at investors.grail.com. Please register for the live event at https://grail-asco-2026-analyst-call.open-exchange.net/.

About the NHS-Galleri Trial (NCT05611632; ISRCTN91431511)
The NHS-Galleri trial is the first and only prospective, randomized, controlled trial to assess the clinical utility and performance of a multi-cancer early detection test for population screening when added to standard care. The trial recruited more than 140,000 asymptomatic participants, aged 50 to 77, and was conducted in partnership with the NHS in England. Participants provided three blood samples over two years, about 12 months apart. The primary objective of the NHS-Galleri trial was to show a reduction in late-stage (III-IV) cancers in people who received the Galleri test compared with those who did not. This was measured in three clinically important groups of cancers, focusing first in a pre-specified group of 12 cancer types that together represent approximately two-thirds of cancer deaths in England and the United States. Secondary objectives include reduction in stage IV cancer; performance of the Galleri test, including positive predictive value and false positive rate; increase in overall cancer detection rate; safety; and healthcare resource utilization.

About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, Calif. with locations in Washington, D.C., North Carolina, and London. 

For more information, visit grail.com.

About Galleri^®
The Galleri^® multi-cancer early detection (MCED) test screens for more than 50 cancer types, including many deadly cancers that currently lack screening options, such as pancreatic, ovarian and liver/bile duct cancers³. The Galleri test is the only MCED test clinically proven through a randomized controlled trial to increase earlier cancer detection (Stage I-III) and reduce Stage IV diagnoses - enabling more patients to have curative treatment⁴. When added to standard-of-care screening, the Galleri test reduced Stage IV diagnosis by more than 20% after the first year of screening across all stageable cancers^4,*. The Galleri test increased cancer detection by screening four times versus standard of care screening alone⁴. The Galleri test has the lowest false positive rate among MCED tests** and the ability to predict the Cancer Signal of Origin with greater than 90% accuracy, helping guide efficient diagnostic evaluation^5,*. The Galleri test is backed by a robust clinical evidence program, with more than 380,000 participants across multiple studies, including the NHS-Galleri trial, the first and only randomized controlled trial for an MCED test. The Galleri test has delivered consistent performance across these studies. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test, or cervical cancer screening. The Galleri test is recommended for adults with an elevated risk for cancer, such as those aged 50 or older.

For more information, visit galleri.com.

**A statistically significant reduction was not observed in combined stage III–IV diagnoses across three screening rounds for the 12 deadly cancers.

**Test performance metrics do not represent results of a head-to-head comparative study. Separate studies have different designs, objectives, and participant populations, which limits the ability to draw conclusions about comparative performance.

Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those age 50 or older. The test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. The Galleri test is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of the test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs, and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False positive (a cancer signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Laboratory/Test Information
The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed — and its performance characteristics were determined — by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes. 

GRAIL Forward Looking Statements
This press release contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "aim," "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," "would," or "will," the negative of these terms, and other comparable terminology. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include statements related to the potential benefits, uses and impacts of the Galleri test, plans for future follow up of the trial and expectations of future data or results we may see from such follow up, extrapolation of trends in the results, comparability of the results to a real world setting, including the similarity of the incidence rounds to steady state screening, the potential survival benefits of Galleri screening, benefits of population screening with Galleri, the applicability of the NHS-Galleri results to the commercial or FDA versions of the Galleri test, and plans to submit the results for publication, among others. 

These statements are only predictions based on our current expectations and projections about future events and trends. There are important factors that could cause our actual results, level of activity, performance, or achievements to differ materially and adversely from those expressed or implied by the forward-looking statements, including those factors and numerous associated risks discussed under the section entitled "Risk Factors" in our Annual Report on Form 10-K for the period ended December 31, 2025. Moreover, we operate in a dynamic and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results, level of activity, performance, or achievements to differ materially and adversely from those contained in any forward-looking statements we may make.

Forward-looking statements relate to the future and, accordingly, are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Although we believe the expectations and projections expressed or implied by the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Our actual results, financial condition and success in our business strategies and operations may differ materially from those indicated in the forward-looking statements. Except to the extent required by law, we undertake no obligation to update any of these forward-looking statements after the date of this press release to conform our prior statements to actual results or revised expectations or to reflect new information or the occurrence of unanticipated events.

¹ Swanton C. NHS-Galleri: Primary Results From a Randomised Controlled Trial to Assess the Clinical Utility of a Multi-Cancer Early Detection (MCED) Test in Population Screening [presentation]. American Society of Clinical Oncology (ASCO) Annual Meeting; 2026 May 29-June 2.
² The 12 cancer types include anus, bladder, colorectal, esophagus, head and neck, liver/bile duct, lung, lymphoma, myeloma/plasma cell neoplasm, ovary, pancreas, stomach.
³ Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806
⁴ Swanton C. NHS-Galleri: Primary Results From a Randomised Controlled Trial to Assess the Clinical Utility of a Multi-Cancer Early Detection (MCED) Test in Population Screening [presentation]. American Society of Clinical Oncology (ASCO) Annual Meeting; 2026 May 29-June 2.
⁵ GRAIL, Inc. False positive rate. [Data on file: GR-2025-0256]

View original content to download multimedia:https://www.prnewswire.com/news-releases/grail-reports-full-results-from-nhs-galleri-trial-demonstrating-substantial-reduction-in-stage-iv-cancer-diagnoses-at-2026-asco-annual-meeting-302786216.html

SOURCE GRAIL, Inc.

FAQ

What did GRAIL (NASDAQ: GRAL) announce about the NHS-Galleri trial at ASCO 2026?

GRAIL announced full NHS-Galleri trial results at ASCO 2026, detailing clinical utility, performance and safety of annual Galleri blood testing. According to GRAIL, 142,250 participants were randomized to Galleri plus standard screening versus standard screening alone over three years in England’s National Health Service.

Did the NHS-Galleri trial meet its primary endpoint for the Galleri test (GRAL)?

The NHS-Galleri trial did not meet its primary endpoint of reducing combined Stage III/IV diagnoses in 12 prespecified cancers within one year after the last appointment. According to GRAIL, the incidence rate ratio was 1.03 with p=0.6324, and follow-up will continue for additional outcomes.

How did Galleri (NASDAQ: GRAL) affect Stage IV cancer diagnoses in the NHS-Galleri trial?

Galleri was associated with fewer Stage IV diagnoses in the 12 prespecified cancers, with reductions of 9%, 22% and 26% across the three screening rounds. According to GRAIL, this secondary endpoint showed a 14% overall Stage IV decrease, with similar 20%+ reductions for all stageable cancers in later rounds.

What impact did Galleri screening have on early-stage (Stage I-II) cancer detection in the NHS-Galleri study?

Galleri increased early-stage diagnoses. According to GRAIL, Stage I-II cancers in the 12 prespecified types rose by 16% after three screening rounds, including large increases in cancers often found late, such as ovarian, esophageal, pancreatic and liver, when added to standard NHS screening programs.

How did adding Galleri (GRAL) to standard screening change overall cancer detection patterns?

Adding Galleri led to more screen-detected and fewer symptom-detected cancers. According to GRAIL, screen-detected cancers increased four-fold, clinically detected cancers after symptomatic presentation fell 21%, and cancers diagnosed after emergency presentation decreased by 25%, suggesting a shift toward planned, earlier diagnosis.

What were the performance metrics of the Galleri multi-cancer early detection test in the NHS trial?

Galleri showed high specificity and moderate sensitivity. According to GRAIL, specificity was 99.55% with a 0.45% false positive rate, positive predictive value was 52.0% overall, Cancer Signal of Origin accuracy was 92.5%, and episode sensitivity was 54.7% for 12 prespecified cancers and 30.7% for all cancers.

Were there any safety concerns reported with Galleri cancer screening in the NHS-Galleri trial?

No serious related adverse events were reported with Galleri screening. According to GRAIL, 1,801 participants (0.91%) had a positive test across three rounds, 937 were diagnosed with cancer, and the safety profile in this large randomized population was consistent with prior North American studies.